Skip to main content
S&P 5007,724.15+0.75%DOW51,167.94+0.47%NASDAQ27,195.32+1.20%BTC$84,877.00+0.30%ETH$2,681.90-0.48%GOLD$4,167.40-0.83%OIL$91.49-1.49%
Smart Investors Daily
SID Premium
LR

NASDAQ · LRMR

Larimar Therapeutics, Inc.

Healthcare · Biotechnology

$3.06

Down-$0.11 (-3.57%)

Updated Oct 2, 2026, 5:24 PM

SID Score

4.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
343.65M
P/E ratio
-2.58
Dividend yield
0.00%
52-week range
$2.92 – $6.00
Volume
858.31K
Avg. volume
2.64M

Price performance · LRMR

LRMR price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 1, 2026

LRMR closed at $3.06 after 20 trading sessions, down 20.10% for the selected period.

Last close
$3.06
Period change
-20.10%
Period low
$3.06
Period high
$4.08
Daily close
View OHLC price history
LRMR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 1, 2026$3.20$3.20$3.04$3.06858.31K
Sep 30, 2026$3.13$3.225$3.075$3.1951.5M
Sep 29, 2026$3.13$3.20$3.115$3.141.04M
Sep 28, 2026$3.04$3.2308$3.03$3.171.67M
Sep 25, 2026$3.32$3.34$3.02$3.0753.05M
Sep 24, 2026$3.85$3.86$3.305$3.323.63M
Sep 23, 2026$3.82$3.90$3.71$3.8652.72M
Sep 22, 2026$3.91$3.965$3.815$3.82702.94K
Sep 21, 2026$3.84$3.885$3.78$3.83579.33K
Sep 18, 2026$3.81$3.88$3.75$3.791.64M
Sep 17, 2026$3.93$4.12$3.80$3.801.2M
Sep 16, 2026$3.93$3.97$3.825$3.931.96M
Sep 15, 2026$3.86$3.94$3.70$3.91856.62K
Sep 14, 2026$3.93$3.98$3.74$3.781.17M
Sep 11, 2026$3.91$4.07$3.85$3.922.13M
Sep 10, 2026$3.82$3.86$3.74$3.85871.39K
Sep 9, 2026$4.03$4.17$3.83$3.87978.8K
Sep 8, 2026$3.76$4.08$3.72$4.0751.04M
Sep 4, 2026$3.82$3.85$3.79$3.83391.99K
Sep 3, 2026$3.90$3.90$3.7741$3.83684.26K

Latest LRMR news

The latest Smart Investors Daily articles mentioning LRMR.

Stock researchCompany · Overview

LRMR research

Overview

Company profile and research snapshot.

Company profile

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.00
Implied upside
—
Analysts
18
LRMR recent ratings
DateFirmRatingTarget
Aug 5, 2026WedbushOutperform—
Jun 30, 2026BairdOutperform—
May 27, 2026JP MorganOverweight—
May 18, 2026WedbushOutperform—
Mar 20, 2026WedbushOutperform—
Open full forecast

News briefing

Generated Oct 2, 2026, 5:11 PM

Why Is LRMR Down Today?

Larimar Therapeutics shares declined 3.43% today despite the company announcing a significant executive leadership appointment. The market's muted reaction suggests investors may be pricing in the leadership change as a neutral development, with broader biotech sector headwinds or profit-taking potentially contributing to the modest sell-off.

    Bottom line: Larimar's 3.43% decline today appears to reflect a neutral market reception to its executive appointment rather than negative company-specific news. Investors should monitor the company's upcoming clinical trial milestones and operational progress under new leadership, as the real test of this hire's value will be whether it translates into accelerated pipeline advancement and improved execution in the quarters ahead.

    Yahoo · Sep 29, 2026

    Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer

    BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to Carole Ben-Maimon, M.D., Larimar’s Chief Executive Officer. Mr. Harlow joins Larimar with more than 25 years of commercial, operational and business development ex

    Yahoo · Sep 9, 2026

    Century Therapeutics Appoints Joseph Truitt to Board of Directors

    PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors. Truitt currently serves as Chief Executive Officer and a member of the Board of Directors of iECURE, Inc., a clinical-stage biotechnology company advancing

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By